These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 34152427)

  • 21. Bendamustine-rituximab in mantle cell lymphoma.
    Lipsky A; Martin P
    Lancet Haematol; 2017 Jan; 4(1):e2-e3. PubMed ID: 27927585
    [No Abstract]   [Full Text] [Related]  

  • 22. Infection risk and antimicrobial prophylaxis in bendamustine-treated patients with indolent non-Hodgkin lymphoma: An Australasian Lymphoma Alliance study.
    Manos K; Churilov L; Grigg A; Di Ciaccio P; Wong J; Chandra Sekaran U; Wight J; Goh Z; Jina H; Butler L; Yannakou CK; Hamad N; Gregory GP; Gangatharan S; Cochrane T; Hawkes EA; Lasica M
    Br J Haematol; 2024 Jul; 205(1):146-157. PubMed ID: 38485116
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group.
    Rueda A; Calvo V; Casanova M; Rodriguez-Abreu D; Aguiar D; Llanos M; Alvarez R; Martinez-Banaclocha N; Alfaro J; Quero C; Blasco A; de la Cruz Merino L; Herrero J; García-Arroyo FR; Provencio M
    Leuk Lymphoma; 2019 Jun; 60(6):1576-1579. PubMed ID: 30516082
    [No Abstract]   [Full Text] [Related]  

  • 24. Long-term outcomes, secondary malignancies and stem cell collection following bendamustine in patients with previously treated non-Hodgkin lymphoma.
    Martin P; Chen Z; Cheson BD; Robinson KS; Williams M; Rajguru SA; Friedberg JW; van der Jagt RH; LaCasce AS; Joyce R; Ganjoo KN; Bartlett NL; Lemieux B; VanderWalde A; Herst J; Szer J; Bar MH; Cabanillas F; Dodds AJ; Montgomery PG; Pressnail B; Ellis T; Smith MR; Leonard JP
    Br J Haematol; 2017 Jul; 178(2):250-256. PubMed ID: 28419413
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Response to bendamustine is associated with a survival advantage in a heavily pretreated patients with AL amyloidosis.
    Milani P; Schönland S; Palladini G; Kimmich C; Basset M; Russo F; Foli A; Perlini S; Bochtler T; Ho AD; Merlini G; Hegenbart U
    Amyloid; 2017 Mar; 24(sup1):56-57. PubMed ID: 28434298
    [No Abstract]   [Full Text] [Related]  

  • 26. [Two cases of malignant lymphoma with reactivation of resolved hepatitis B virus infection after bendamustine hydrochloride monotherapy].
    Hiraki Y; Kawano A; Shigematsu H; Miki K; Nomura H; Shimoda S
    Nihon Shokakibyo Gakkai Zasshi; 2016 Sep; 113(9):1582-7. PubMed ID: 27593368
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of AL amyloidosis with bendamustine: a study of 122 patients.
    Milani P; Schönland S; Merlini G; Kimmich C; Foli A; Dittrich T; Basset M; Müller-Tidow C; Bochtler T; Palladini G; Hegenbart U
    Blood; 2018 Nov; 132(18):1988-1991. PubMed ID: 30108065
    [No Abstract]   [Full Text] [Related]  

  • 28. BeEAM (bendamustine, etoposide, cytarabine, melphalan) prior to autologous stem cell transplant for chemosensitive relapses in patients with follicular lymphoma: a prospective multicentre phase II study in Lymphoma Study Association centres
    Ghesquières H; Dalban C; Nicolas-Virelizier E; Jardin F; Le Bras F; Le Gouill S; Casasnovas O; Vizoso S; Hernandez C; Metzger S; Pérol D; Cartron G
    Br J Haematol; 2021 Feb; 192(3):e94-e98. PubMed ID: 33421031
    [No Abstract]   [Full Text] [Related]  

  • 29. Safety and efficacy of single-agent bendamustine after failure of brentuximab vedotin in patients with relapsed or refractory hodgkin's lymphoma: experience with 27 patients.
    Zinzani PL; Vitolo U; Viviani S; Corradini P; Motta G; Tani M; Cascavilla N; Hohaus S; Merli F; Argnani L; Broccoli A
    Clin Lymphoma Myeloma Leuk; 2015 Jul; 15(7):404-8. PubMed ID: 25840816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity.
    Cheah CY; Nastoupil LJ; McLaughlin P; Fanale MA; Neelapu SS; Fayad LE; Hagemeister FB; Fowler NH
    Br J Haematol; 2016 Nov; 175(3):531-533. PubMed ID: 26683805
    [No Abstract]   [Full Text] [Related]  

  • 32. Prolonged lymphocytopenia after bendamustine therapy in patients with relapsed or refractory indolent B-cell and mantle cell lymphoma.
    Saito H; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto K; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Taniguchi H; Tobinai K
    Blood Cancer J; 2015 Oct; 5(10):e362. PubMed ID: 26495859
    [No Abstract]   [Full Text] [Related]  

  • 33. Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study.
    Reboursiere E; Le Bras F; Herbaux C; Gyan E; Clavert A; Morschhauser F; Malak S; Sibon D; Broussais F; Braun T; Fornecker LM; Garidi R; Tricot S; Houot R; Joly B; Abarah W; Choufi B; Pham AD; Gac AC; Fruchart C; Marin E; Safar V; Parcelier A; Maisonneuve H; Bachy E; Cartron G; Jaccard A; Tournilhac O; Rossi C; Schirmer L; Martignoles JA; Gaulard P; Tilly H; Damaj G;
    Oncotarget; 2016 Dec; 7(51):85573-85583. PubMed ID: 27458168
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Influence of rituximab plus bendamustine chemotherapy on the immune system in patients with refractory or relapsed follicular lymphoma and mantle cell lymphoma.
    Ito K; Okamoto M; Ando M; Kakumae Y; Okamoto A; Inaguma Y; Tokuda M; Yanada M; Yamada S; Emi N
    Leuk Lymphoma; 2015 Apr; 56(4):1123-5. PubMed ID: 24828861
    [No Abstract]   [Full Text] [Related]  

  • 35. Overall Survival Benefit in Patients With Rituximab-Refractory Indolent Non-Hodgkin Lymphoma Who Received Obinutuzumab Plus Bendamustine Induction and Obinutuzumab Maintenance in the GADOLIN Study.
    Cheson BD; Chua N; Mayer J; Dueck G; Trněný M; Bouabdallah K; Fowler N; Delwail V; Press O; Salles G; Gribben JG; Lennard A; Lugtenburg PJ; Fingerle-Rowson G; Mattiello F; Knapp A; Sehn LH
    J Clin Oncol; 2018 Aug; 36(22):2259-2266. PubMed ID: 29584548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytomegalovirus retinitis in relapsed or refractory low-grade B cell lymphoma patients treated with bendamustine.
    Yamasaki S; Kohno K; Kadowaki M; Takase K; Iwasaki H
    Ann Hematol; 2017 Jul; 96(7):1215-1217. PubMed ID: 28447162
    [No Abstract]   [Full Text] [Related]  

  • 38. The discovery and the development of bendamustine for the treatment of non-Hodgkin lymphoma.
    Munakata W; Tobinai K
    Expert Opin Drug Discov; 2016 Nov; 11(11):1123-1130. PubMed ID: 27598460
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
    Haukaas FS; Ohna A; Krivasi T
    Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High incidence of reversible renal toxicity of dose-intensified bendamustine-based high-dose chemotherapy in lymphoma and myeloma patients.
    Prediletto I; Farag SA; Bacher U; Jeker B; Mansouri Taleghani B; Brégy R; Zander T; Betticher D; Egger T; Novak U; Pabst T
    Bone Marrow Transplant; 2019 Dec; 54(12):1923-1925. PubMed ID: 30890768
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.